30,510 Shares in Medline $MDLN Acquired by Amundi

Key Points

• Amundi acquired 30,510 Medline shares during the first quarter, establishing a position valued at approximately $1.36 million. Several other major institutional investors also recently initiated sizable stakes.
• Medline reported quarterly EPS of $0.50, beating the $0.32 consensus estimate, on roughly $7.68 billion in revenue. The company raised its 2026 organic-sales-growth outlook to 9%–10%, but lowered adjusted EBITDA guidance to $3.3 billion–$3.4 billion, pointing to potential margin pressures.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $48.50 versus a recent share price near $35. However, insider selling—including a large GIC Private transaction—and reported legal investigations related to prior FDA violations present risks.

Amundi bought a new position in Medline (NASDAQ:MDLN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,510 shares of the company's stock, valued at approximately $1,358,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Carlyle Group Inc. acquired a new stake in shares of Medline in the fourth quarter valued at about $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new position in Medline in the 4th quarter valued at about $4,179,591,000. Vanguard Group Inc. purchased a new position in Medline in the 4th quarter valued at about $793,278,000. Morgan Stanley acquired a new stake in shares of Medline during the fourth quarter valued at about $636,807,000. Finally, Capital Research Global Investors purchased a new stake in shares of Medline during the fourth quarter worth about $620,937,000.

Analysts Set New Price Targets

MDLN has been the subject of several research analyst reports. Sanford C. Bernstein lowered their price objective on Medline from $56.00 to $54.00 and set an "outperform" rating for the company in a report on Thursday, May 7th. Stifel Nicolaus lowered their price objective on shares of Medline from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Thursday. Truist Financial dropped their price objective on shares of Medline from $56.00 to $47.00 and set a "buy" rating on the stock in a research note on Thursday. Royal Bank Of Canada cut their target price on shares of Medline from $53.00 to $46.00 and set an "outperform" rating on the stock in a report on Thursday. Finally, Robert W. Baird set a $42.00 target price on Medline in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $48.50.

Medline Price Performance

Shares of NASDAQ:MDLN opened at $35.23 on Friday. Medline has a 1-year low of $32.81 and a 1-year high of $50.88. The firm has a market capitalization of $46.28 billion and a PE ratio of 110.09. The company has a current ratio of 4.33, a quick ratio of 2.51 and a debt-to-equity ratio of 0.66. The business's 50 day moving average is $38.22 and its 200-day moving average is $41.72.

Medline (NASDAQ:MDLN - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. Sell-side analysts predict that Medline will post 1.49 earnings per share for the current year.

Insiders Place Their Bets

In other Medline news, major shareholder Private Ltd Gic sold 1,976,618 shares of the company's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $35.60, for a total value of $70,367,600.80. Following the sale, the insider directly owned 25,264,760 shares in the company, valued at $899,425,456. This represents a 7.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Douglas P. Golwas sold 100,000 shares of the company's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the sale, the insider owned 23,899 shares in the company, valued at $878,766.23. This trade represents a 80.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,348,612 shares of company stock worth $83,654,149 over the last quarter. Company insiders own 0.81% of the company's stock.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
• Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
• Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
• Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation

Medline Profile

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source